IFPMA

Ahead of UN General Assembly, pharmaceutical industry underscores need for pandemic preparedness plans to support innovation and equity

Retrieved on: 
Wednesday, September 13, 2023
Biotechnology, Health, Public Policy, Pharmaceutical, Medical Devices, Research, Infectious Diseases, Genetics, Government, Science, COVID-19, Vaccine, Developing Countries Vaccine Manufacturers Network, Biotechnology Innovation Organization, UN General Assembly Resolution 60/147, Progress, Pandemic, Politics, UN, IFPMA

Progress will require coordinated action by industry, governments, and multilateral organizations to put in place the right incentives that support the pipeline of vaccines and treatments for future pandemics.

Key Points: 
  • Progress will require coordinated action by industry, governments, and multilateral organizations to put in place the right incentives that support the pipeline of vaccines and treatments for future pandemics.
  • This must include scientists having rapid access to pathogens and genetic information and the ability for companies to partner on a voluntary basis.
  • Alongside the focus on ensuring greater equity of access, IFPMA has called for these measures to be central to pandemic preparedness plans, including in the Political Declaration being considered by the UN General Assembly.
  • The plans were endorsed by the Developing Countries Vaccines Manufacturing Network and the Biotechnology Industry Organization .

Biotechs, Developing Countries Vaccine Manufacturers and Pharma Unite Behind a Proposal to G20 and G7 Offering a Practical Solution for Better Access to Vaccines for Future Pandemics

Retrieved on: 
Sunday, October 23, 2022
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, ACT, IFPMA, Time, G7, Pandemic, Vaccine, Biotechnology Innovation Organization, COVID, Organization, Industry, Biotechnology, COVID 19, Investor, Research, Access, First Nations in Ontario, Multimedia, Technology, Infection, COVAX, United Nations, List of international sports federations, Association, Lists of countries and territories, COVID-19, BIO, Solution, G20, Pharmaceutical industry

The proposal intends to ensure that new vaccines developed for future pandemics would reach priority vulnerable populations wherever they live at the same time, and as rapidly as possible.

Key Points: 
  • The proposal intends to ensure that new vaccines developed for future pandemics would reach priority vulnerable populations wherever they live at the same time, and as rapidly as possible.
  • View the full release here: https://www.businesswire.com/news/home/20221023005064/en/
    BIO, DCVMN, IFPMA: Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7 offering a practical solution for better access to vaccines for futurepandemics (Graphic: Business Wire)
    To date nearly 16 billion doses of vaccines for COVID 19 have been produced.
  • Specifically, the proposal offers to reserve a real-time allocation of vaccines production for vulnerable populations in lower-income countries.
  • All their members are fully committed to the goal of COVAX to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.

Last Chance to Register for This Biosimilars Training Course: Covering the Regulatory Pathways and Challenges for Both the EU and US (October 11-12, 2022) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Health, Biotechnology, Master of Science, IFPMA, EFPIA, EMEA, University of Surrey, Patient, University, Publishing, Industry, IMI, Artificial intelligence, Marloes, Hoffmann-La Roche, University College Utrecht, Pharmaceutical medicine, List of life sciences, Pharmaceutical industry

in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.

Key Points: 
  • in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.
  • He has gained a wealth of experience and a comprehensive view on what information is needed to evaluate the benefit/risk ratio of drugs for patients and healthy volunteers.
  • He applies new technologies and Artificial Intelligence to facilitate the business and let people focus on what they can do best.
  • Also, she contributed to the ongoing IMI PREFER project in Europe, focused on the generation and use of patient preference data.

Global Moving Bed Bioreactor Market 2022: Inefficient Irrigation Within Agriculture to Boost Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Other Natural Resources, Natural Resources, COVID-19, IFPMA, Phosphorus, Water, CAGR, Food, Lists of countries and territories, Nitrogen, Technology, Biomass, Research, City, Lake, Solution, Adoption, Agriculture, Awareness, River, Fine chemical, Sewage, Video game, Growth

The "Moving Bed Bioreactor Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Moving Bed Bioreactor Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The market for moving bed bioreactor (MBBR) is expected to register a CAGR of around 15%, during the forecast period.
  • However, lack of awareness and funding toward moving bed bioreactors is likely to restraint the market.
  • Inefficient irrigation within agriculture is also likely to boost the demand for MBBR, during the forecast period.

Pharma Proposes to Work with G7 and G20 on a Joint Solution for Better Access to Vaccines and Treatments Around the World for Future Pandemics

Retrieved on: 
Tuesday, July 19, 2022
Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, Biotechnology, IFPMA, COVAX, Health in Indonesia, Intellectual property, CEO, G20, Patient, Investment, COVID-19 vaccine, Solution, Pandemic, UCB, United Nations, Life, First Nations in Ontario, Berlin, Industry, COVID-19, Hearing, Health, Panic, G7, Vaccine, Private sector, Investor, Global health, Pharmaceutical industry, Animal

The industry, which developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for the even more equitable rollout of vaccines, treatments and diagnostics for future pandemics.

Key Points: 
  • The industry, which developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for the even more equitable rollout of vaccines, treatments and diagnostics for future pandemics.
  • It also emphasizes that without robust pandemic plans to deliver pandemic vaccines, treatments and diagnostics and care to populations in all countries, attempts to improve equity will falter.
  • Achieving more equitable access to vaccines and treatments in future pandemics will require close collaboration of governments, private sector and civil society.
  • Our proposal is just a first step along the way to what I believe has the potential to be a transformational solution for future pandemics.

Worldwide Mass Spectrometry Industry to 2027 - by Mass Analyzer/Ion Separation, Industry and Geography

Retrieved on: 
Thursday, June 23, 2022
Growth, Conference, USD, Coronavirus, Federalisation of the European Union, Atomic mass, Biotechnology Innovation Organization, Safety, List of international sports federations, Industry, EUR, Field line, Technology, Lists of countries and territories, Congressional Budget Office, Acceleration, IFPMA, United Nations Conference on Trade and Development, BIO, Research, Investment, EFPIA, Ratio, United Nations, UNCTAD, CAGR, Biotechnology, European Federation of Pharmaceutical Industries and Associations, Mass spectrometry, Population, Ion, Mass, Fine chemical

Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested.

Key Points: 
  • Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested.
  • Mass spectrometry also helps understand different chemical properties and structural orientations of the molecules present in the testing sample.
  • The real-life applications of the mass spectrometry market are vast in pharmaceutical, drug, biotechnology, and other similar sectors.
  • With high R&D investments and government-aided funding, the mass spectrometry market share worldwide is projected to rise for the US in the forecast period.

Global Mass Spectrometry Market Report (2022 to 2027) - Players Include 908 Devices, AB SCIEX, Advion and Agena Biosciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Health, Chemicals, Plastics, Biometrics, Manufacturing, Other Science, Science, Pharmaceutical, CAGR, Biotechnology Innovation Organization, Industry, United Nations Conference on Trade and Development, European Federation of Pharmaceutical Industries and Associations, Ion, IFPMA, Congressional Budget Office, Atomic mass, UNCTAD, Lists of countries and territories, BIO, Biotechnology, Research, Technology, Ratio, Growth, USD, Acceleration, List of international sports federations, Mass spectrometry, Investment, EUR, United Nations, Mass, Field line, EFPIA, Conference, Federalisation of the European Union, Fine chemical

Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested.

Key Points: 
  • Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested.
  • Mass spectrometry also helps understand different chemical properties and structural orientations of the molecules present in the testing sample.
  • The real-life applications of the mass spectrometry market are vast in pharmaceutical, drug, biotechnology, and other similar sectors.
  • The United States of America is projected to grow substantially in the global mass spectrometry market share.

IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference

Retrieved on: 
Friday, June 17, 2022
Research, Infectious Diseases, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Professional Services, Solution, Intellectual property, Industry, WTO, COVID-19, Global health, Vaccine, IFPMA, Technology, TRIPS, World Trade Organization, Research, MC12, Ministerial Conference, World, World Trade, History, United Nations, Patient, IP, First Nations in Ontario, Conference, Life, Pharmaceutical industry

Todays decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and development and innovating.

Key Points: 
  • Todays decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and development and innovating.
  • It incorrectly points to intellectual property (IP) as a barrier to the pandemic response rather than an enabler bringing healthcare solutions, safely and quickly to patients.
  • IP has supported the fastest development and scale-up of safe and effective vaccines in history, with 13.9 billion COVID-19 vaccines produced to date.
  • Todays decision sends a dangerous signal not only to the pharmaceutical industry but to all innovative sectors.

Clinical Trials Management System Market Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 6, 2022
Health, Clinical Trials, Cloud, Conditional sentence, Clinical trial management system, Oracle, Clinical trial, Biotechnology, CTMS, Component, USD, AI, IQVIA, Lundbeck, Chapter Three, List of international sports federations, Enterprise, IFPMA, Solution, Investment, Vaccine, Machine learning, EHR, Cancer, Neurology, Medication, Infection, Cros, COVID-19, Adoption, Prevalence, EDC, Drug development, Patient safety, Calendar, CAGR, ML, Retail, Pharmaceutical industry, Fine chemical, Medical device, Medical imaging

The "Clinical Trials Management System Market Size, Share & Trends Analysis Report by Solution Type (Enterprise, Site), by Delivery Mode (Web & Cloud-based, On-premise), by Component, by End User, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trials Management System Market Size, Share & Trends Analysis Report by Solution Type (Enterprise, Site), by Delivery Mode (Web & Cloud-based, On-premise), by Component, by End User, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical trials management system market size is anticipated to reach USD 4.72 billion by 2030.
  • The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.
  • The Clinical Trial Management System offered by SimpleTrials, for instance, includes features such as contact management, calendar & monitoring, project planning, document management & eTMF, contract & payment system, subject tracking, visit report authoring & letter generation, EDC integration, and reporting and business analytics.

Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global

Retrieved on: 
Tuesday, February 8, 2022
Government, Private Securities Litigation Reform Act, GLOBE, Industry, Forward-looking statement, Growth, HIV, EFPIA, Multiple sclerosis, Immune system, Commerce, Leadership, SAN, Infection, Technology, Spinal muscular atrophy, Patient, Securities and Exchange Commission (Philippines), Safety, Federalisation of the European Union, IFPMA, Biotechnology, Biogen, Drug development, U.S. Securities and Exchange Commission, List of international sports federations, Hepatitis B virus, Amyotrophic lateral sclerosis, COVID-19, Management, Pharmaceutical industry

SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022.

Key Points: 
  • SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022.
  • Johanna is an experienced commercial executive with an impressive range of global operational expertise and leadership success, and I am thrilled to have the opportunity to work with her again, said Dr. Scangos.
  • Prior to joining Vir, Friedl-Naderer was President of Europe, Canada & Partner Markets for Biogen, where she served on the companys Global Leadership Team.
  • Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.